Blood protein may help track disease activity in people with aHUS
Researchers have identified that levels of the blood protein subunit FXIII-B may serve as a biomarker for tracking disease activity in patients with atypical hemolytic uremic syndrome (aHUS). The study suggests that monitoring these protein patterns could help distinguish between acute episodes and remission.
Why it matters
This discovery could lead to more effective clinical monitoring and personalized treatment strategies for patients suffering from this rare and severe blood disorder.
Study finds distinct factor XIII patterns during acute episodes and remission
Factor XIII (FXIII) activity was lower in samples collected during acute episodes of atypical hemolytic uremic syndrome (aHUS), while levels of one of its subunits, FXIII-B, were higher in samples collected during remission, suggesting FXIII-B may serve as a marker of disease activity.
“Free FXIII-B emerges as a promising biomarker candidate in this rare but severe disease,” researchers wrote in “ Beyond Complement: Comprehensive Assessment of Factor XIII Plasma Dynamics and Genetics in Atypical Haemolytic Uraemic Syndrome ,” which was published in Research and Practice in Thrombosis and Haemostasis .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in